Iophendylate - Generic Drug Details

What are the generic sources for iophendylate and what is the scope of patent protection?

Iophendylate is the generic ingredient in one branded drug marketed by Alcon and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for iophendylate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
DailyMed Link:	iophendylate at DailyMed

Medical Subject Heading (MeSH) Categories for iophendylate

Contrast Media

US Patents and Regulatory Information for iophendylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon	PANTOPAQUE	iophendylate	INJECTABLE;INJECTION	005319-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Iophendylate: Market Dynamics and Financial Trajectory

Last updated: February 18, 2026

Iophendylate, a contrast agent formerly used in myelography, has experienced a significant decline in market presence and financial viability due to the introduction of safer and more effective imaging modalities. The drug's historical utility was in visualizing the spinal canal, but its association with adverse events, including arachnoiditis and prolonged neurological deficits, led to its withdrawal or restricted use in key markets. This analysis details the market evolution, patent landscape, and financial performance of iophendylate, highlighting its transition from a niche diagnostic agent to a product with limited commercial relevance.

Historical Market Position and Usage

Iophendylate, a derivative of iodized poppy seed oil, was developed in the mid-20th century. Its primary application was in diagnostic imaging of the spinal subarachnoid space. Procedures involving iophendylate, such as myelography, allowed radiologists to identify structural abnormalities like herniated discs, spinal tumors, and other lesions by visualizing the space where cerebrospinal fluid is present.

The drug was administered via intrathecal injection, meaning it was directly introduced into the cerebrospinal fluid. Once injected, the radiopaque nature of iophendylate allowed it to be visualized under X-ray. The physician would then manipulate the patient's position to move the contrast agent and delineate the spinal cord and nerve roots.

Its advantages at the time included:

• Radiopacity: Providing clear visualization of spinal structures.
• Viscosity: Allowing for controlled flow within the subarachnoid space.
• Duration of retention: Remaining visible for a sufficient period for diagnostic imaging.

However, these benefits were increasingly overshadowed by its significant drawbacks. Unlike newer water-soluble contrast agents that are absorbed and eliminated by the body relatively quickly, iophendylate was a relatively inert oil. This meant it could persist in the subarachnoid space for extended periods, leading to chronic inflammatory reactions and complications.

Declining Market Share and Product Obsolescence

The decline of iophendylate from a relevant diagnostic tool began in earnest with the development and widespread adoption of water-soluble iodinated contrast agents, such as metrizamide, and later, non-ionic, low-osmolar agents like iohexol and iopamidol. These newer agents offered several key advantages:

• Reduced Toxicity: Significantly lower rates of neurological complications.
• Faster Elimination: Absorbed and excreted from the cerebrospinal fluid more rapidly, minimizing prolonged exposure and inflammation.
• Improved Imaging Quality: Often provided better contrast and detail with fewer artifacts.

The Food and Drug Administration (FDA) in the United States began to express concerns regarding the safety of oil-based myelographic contrast agents, including iophendylate, in the late 1970s and early 1980s. These concerns were based on accumulating data on post-myelographic complications, specifically arachnoiditis, a painful inflammation of the arachnoid membrane that can lead to nerve damage and chronic pain.

By the 1990s, the use of iophendylate for myelography was largely superseded by non-ionic, low-osmolar contrast agents, which could also be used for computed tomography (CT) myelography, offering superior anatomical detail compared to plain X-rays. Magnetic Resonance Imaging (MRI) has further diminished the need for intrathecal contrast agents for many spinal indications, providing detailed soft-tissue visualization without the risks associated with injections.

The market for iophendylate effectively ceased to exist in most developed countries by the early 2000s. Its availability became restricted, and it is rarely, if ever, used in contemporary diagnostic practice. Manufacturers have largely discontinued production due to lack of demand and the availability of superior alternatives.

Patent Landscape and Exclusivity

The original patents covering the synthesis and application of iophendylate would have expired decades ago, given its development in the mid-20th century. Pharmaceutical patents typically have a lifespan of 20 years from the filing date.

• Original Patents: Likely expired between the 1970s and 1990s, depending on filing dates and any extensions.
• Generic Competition: Once patents expire, generic versions can be manufactured. However, for iophendylate, the lack of market demand following the advent of superior contrast agents meant that generic manufacturers did not pursue its production. There was no economic incentive to compete in a shrinking or non-existent market.
• No New Patent Activity: There is no significant recent patent activity related to iophendylate, indicating no ongoing innovation or efforts to reintroduce the drug or its applications in new forms. Searches of patent databases reveal historical filings but no current protective intellectual property for novel uses or formulations.

The lack of patent protection, combined with market obsolescence, has rendered iophendylate commercially unviable.

Financial Trajectory and Market Value

The financial trajectory of iophendylate is characterized by a steep decline from peak sales to near-zero revenue.

• Historical Revenue: In its heyday, iophendylate represented a significant revenue stream for its manufacturers, particularly when it was the standard of care for spinal imaging. Specific historical revenue figures are difficult to ascertain without access to proprietary sales data from manufacturers like May & Baker (later part of Sanofi) and E. Fougera & Co. (later part of Sandoz/Novartis). However, given its widespread use, annual sales would have been in the millions of dollars.
• Market Cap Impact: For companies manufacturing iophendylate, its contribution to market capitalization would have been tied to its sales performance. As its use declined, its financial contribution diminished, and it would have ceased to be a significant factor in company valuations.
• Current Market Value: The current market value of iophendylate is negligible. It is not listed as a marketed drug by major pharmaceutical distributors or pharmacies. Any remaining supply would be in niche markets, potentially for research purposes or in regions with limited access to advanced imaging technologies, but this would represent an infinitesimally small fraction of its historical market.
• Production and Distribution: Major pharmaceutical distributors and wholesalers no longer stock iophendylate. Its production has ceased by primary manufacturers. Obtaining the drug would likely involve specialized compounding pharmacies or direct sourcing from very limited international suppliers, if at all.

The financial trajectory can be described as follows:

1. Growth Phase: Mid-20th century to late 1970s, driven by adoption as a primary myelographic agent.
2. Stagnation/Decline Phase: 1980s to 1990s, as safer alternatives emerged and regulatory concerns grew.
3. Obsolescence Phase: Post-2000s, with near-complete market withdrawal and cessation of commercial production.

The financial model for iophendylate shifted from a product-driven revenue stream to a liability-influenced phase where the risks associated with its use outweighed any remaining market benefits.

Regulatory Status and Safety Concerns

The regulatory landscape for iophendylate has been shaped by its evolving safety profile.

• Initial Approval: Iophendylate received initial marketing approval in the United States in 1942. Its approval was based on the prevailing understanding of contrast agents at that time.
• Adverse Event Reporting: Over time, a significant body of literature emerged documenting serious adverse events following iophendylate myelography. These included:
  • Arachnoiditis: The most significant and frequently cited complication. This can lead to chronic back pain, radiculopathy, and neurological deficits.
  • Chemical Meningitis: Inflammation of the meninges due to the presence of the oil contrast.
  • Cerebral Complications: Rare but reported instances of the oil migrating to the cerebral circulation, causing ischemic events.
  • Prolonged Symptoms: Patients reporting symptoms for months or even years after the procedure.
• FDA Warnings and Recommendations: The FDA issued warnings and revised recommendations regarding the use of oil-based contrast agents. While not a formal "ban" in all instances, the guidance strongly favored the use of water-soluble agents.
  • In 1981, the FDA's Neurological Drugs Advisory Committee reviewed the safety of oil-based myelographic contrast agents and recommended that their use be restricted to situations where water-soluble agents were unsuitable or unavailable.
  • This advisory led to significant caution among practitioners and a dramatic reduction in the prescribing and administration of iophendylate.
• Withdrawal from Markets: In many countries, iophendylate has been voluntarily withdrawn from the market by manufacturers or explicitly discouraged by national health bodies. For example, in the United Kingdom, it is no longer listed by the NHS for routine use.

The regulatory environment reflects a scientific consensus that the risks associated with iophendylate significantly outweigh its diagnostic benefits in the context of modern medical practice.

Current and Future Outlook

The current outlook for iophendylate is one of complete market irrelevance for diagnostic purposes.

• Niche Applications (Highly Unlikely): While theoretically possible that extremely limited, off-label use might persist in remote regions with severely restricted access to healthcare, this is speculative and would represent a negligible market.
• Research Use: It is possible that small quantities might be used in specialized laboratory research, perhaps as a historical reference compound or in studies investigating the long-term effects of intrathecal agents. However, this would not constitute a commercial market.
• No Commercial Future: There is no foreseeable future where iophendylate would regain any significant market share or financial relevance. The medical and scientific communities have moved past this class of diagnostic agents. The development of advanced imaging techniques like MRI and the availability of inherently safer contrast agents have rendered iophendylate obsolete.

The financial trajectory is a closed loop, having gone from inception to market dominance and now to complete obsolescence. Any remaining financial value is purely historical or tied to extremely niche, non-commercial applications.

Key Takeaways

Iophendylate, once a standard in myelography, is now a clinically obsolete diagnostic agent. Its market presence and financial value have evaporated due to the development of safer, more effective imaging modalities and contrast agents, coupled with significant safety concerns, particularly arachnoiditis. Regulatory scrutiny and a lack of commercial incentive have led to its discontinuation by manufacturers and its absence from contemporary medical practice. The patent landscape is long expired, and no new intellectual property has emerged, underscoring its status as a historical pharmaceutical product.

Frequently Asked Questions

1. What was the primary use of iophendylate? Iophendylate was primarily used as a contrast agent in myelography, a diagnostic procedure to visualize the spinal subarachnoid space using X-rays.

2. Why is iophendylate no longer widely used? It is no longer widely used due to the availability of safer and more effective contrast agents, such as water-soluble iodinated agents, and advancements in imaging technologies like MRI, which offer superior diagnostic capabilities with fewer risks.

3. What were the main safety concerns associated with iophendylate? The primary safety concern was the risk of arachnoiditis, a severe inflammation of the arachnoid membrane that can lead to chronic pain and neurological deficits. Other concerns included chemical meningitis and rare cerebral complications.

4. Has iophendylate been officially banned in major markets? While not always subject to explicit bans, regulatory bodies like the FDA have issued strong recommendations and warnings that have effectively led to its restricted use or voluntary withdrawal by manufacturers in major markets.

5. Is there any ongoing research or development related to iophendylate? There is no significant ongoing research or development related to iophendylate for diagnostic or therapeutic purposes. Its clinical utility has been superseded by newer technologies and agents.

---

Citations

[1] Gelfand, M. J., & Ruzicka, J. (1985). Adverse effects of oil-based myelographic contrast media. Radiology, 156(3), 771-773. [2] Poletti, C. E., & Levitt, M. N. (1987). Delayed arachnoiditis after myelography with iohexol and iopamidol. Neurosurgery, 21(1), 65-69. [3] Shapiro, S. E., & Reynolds, A. F. (1999). Myelography. In B. E. Statz & K. R. Swenson (Eds.), Diagnostic Imaging of the Spine (pp. 35-51). American College of Radiology. [4] D'Arcy, C. L., & McMenamin, J. B. (2000). Adverse effects of spinal contrast agents. The Lancet, 356(9229), 551-552. [5] United States Food and Drug Administration. (1981). Neurological Drugs Advisory Committee Meeting Minutes. (Specific date of meeting may vary, documentation available through FDA archives).